4-Amino-6-arylamino-pyrimidine-5-carbaldehyde hydrazones as potent ErbB-2/EGFR dual kinase inhibitors.Xu, G., Abad, M.C., Connolly, P.J., Neeper, M.P., Struble, G.T., Springer, B.A., Emanuel, S.L., Pandey, N., Gruninger, R.H., Adams, M., Moreno-Mazza, S., Fuentes-Pesquera, A.R., Middleton, S.A.
(2008) Bioorg Med Chem Lett 18: 4615-4619
- PubMed: 18653333
- DOI: https://doi.org/10.1016/j.bmcl.2008.07.020
- Primary Citation of Related Structures:
- PubMed Abstract:
Members of a novel class of 4-amino-6-arylamino-pyrimidine-5-carbaldehyde hydrazones were identified as potent dual ErbB-2/EGFR kinase inhibitors using concept-guided design approach. These compounds inhibited the growth of ErbB-2 over-expressing human tumor cell lines (BT474, N87, and SK-BR-3) in vitro. Compound 15 emerged as a key lead and showed significant ability to inhibit growth factor-induced receptor phosphorylation in SK-BR-3 cells (IC(50)=54 nM) and cellular proliferation in vitro (IC(50)=14, 58, and 58 nM for BT474, N87, and SK-BR-3 respectively). The X-ray co-crystal structure of EGFR with a close analog (17) was determined and validated our design rationale.
Johnson & Johnson Pharmaceutical Research and Development, Medicinal Chemistry, 8 Clarke Drive, Cranbury, NJ 08512, USA. firstname.lastname@example.org